[1. Primary hemostasis [cit 2017-01-29]. Available on webpage: https://www.google.sk/search?q=primaryhemostasis+pictures&biw=1366&bih=622&noj=1&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwiSoZek1fRAhVEtBoKHRRCA0kQ7AkINA#imgrc=nmJjzJyX3BW8LM%3A]Search in Google Scholar
[2. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111: 733-744.]Search in Google Scholar
[3. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.10.1055/s-2007-995840]Search in Google Scholar
[4. Heilmann EJ, Kundu SK, Sio R, Garcia C, Gomez R, Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 1997; 87: 159-164.10.1016/S0049-3848(97)00115-1]Search in Google Scholar
[5. Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyzer. Platelets 2000; 11: 320-324.10.1080/0953710005014473111083456]Search in Google Scholar
[6. Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost 2001;85:369-370.10.1055/s-0037-1615707]Search in Google Scholar
[7. Lassila R. Platelet function tests in bleeding disorders. Semin Thromb Hemost 2016; 42(3): 185-190.10.1055/s-0036-157130726886396]Search in Google Scholar
[8. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-163.10.1067/mlc.2001.11740611528368]Search in Google Scholar
[9. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9: 407-415.10.1097/00062752-200209000-0000412172459]Search in Google Scholar
[10. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130: 3-10.10.1111/j.1365-2141.2005.05511.x15982339]Search in Google Scholar
[11. Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost 2005;94:1213-1218.10.1160/TH05-06-042416411396]Search in Google Scholar
[12. Franchini M. The platelet-function analyzer (PFA-100) for evaluating primary hemostasis. Hematology 2005; 10: 177-181.10.1080/1024533040002609716019466]Search in Google Scholar
[13. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995; 21: 106-12.10.1055/s-0032-13136127660150]Search in Google Scholar
[14. Favaloro EJ, Bonar R. External quality assessment/proficiency testing and internal quality control for the PFA-100 and PFA-200: an update. Semin Thromb Hemost 2014; 40(2): 239-253.10.1055/s-0034-136584424497116]Search in Google Scholar
[15. Scavone M, Germanovich K, Fermia EA, et al. Usefulness of the INNOVANCE PFA P2Y test cartridge for the detection of patients with congenital defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Res 2014; 133(2): 254-256.10.1016/j.thromres.2013.11.02224331208]Search in Google Scholar
[16. PFA-100 System [cit. 2017/01/29]. Available on webpage: https://usa.healthcare.siemens.com/he-mostasis/systems/pfa-100]Search in Google Scholar
[17. Platelet Research Laboratory. Techniques availables [cit. 2017/01/29]. Available on webpage: http://- www.platelet-research.org/1/techniques_pfa.htm]Search in Google Scholar
[18. Disorders of primary hemostasis: lecture 5 [cit. 2017/01/29]. Available on webpage: http:// www.sli-deshare.net/shababali1/lecture-5-fall-2014-pdf]Search in Google Scholar
[19. Kenichi A Tanaka The Assessment of platelet function. Journal Compilation © 2006 LMS Trans - fusion Alternatives in Transfusion Medicine 2, 95- 105.Available on webpage: https://www.researchgate.net/publication/227625147The_assessmentofplateletfunction .10.1111/j.1778-428X.2006.00018.x]Search in Google Scholar
[20. Favaloro EJ. Internal quality control and external quality assurance of platelet function tests. Semin Thromb Hemost 2009; 35(2): 139-149.10.1055/s-0029-122032219408187]Search in Google Scholar
[21. Zaffuto BJ, Coley GW, Connolly GC, et al. ABO immune complex formation and impact on platelet function, red cell structural integrity and haemostasis: an in vitro model of ABO non-identical transfusion. Vox Sang 2016; 110(3): 219-226.10.1111/vox.1235426528766]Search in Google Scholar
[22. Peerschke EI, Castellone DD, Stroobants AK, et al. Reference range determination for whole- blood platelet aggregation using Multiplate analyzer. Am J Clin Pathol 2014; 142(5): 647-656.10.1309/AJCPP43SEYCBJLHJ25319980]Search in Google Scholar
[23. Poujoul C,Nurden A,Papponeau A, Heilmann E, Nurden P. Ultrastructural analysis of the distribution of von Willebrand factor and fibrinogen in platelet aggregates formed in the PFA-100. Platelets 1998; 9: 381-9.10.1080/0953710987645616793722]Search in Google Scholar
[24. Young-Uk Cho, Seongsoo Jang, Chan-Jeoung Park, . Variables that affect platelet function analyzer-100 (PFA-100) closure times and establishment of reference intervals in Korean adults. Ann Clin Lab Sci 2008 ;38(3):247-53.]Search in Google Scholar
[25. Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ. Performance of the platelet function analyzer PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999; 10: 25-31.10.1097/00001721-199901000-0000410070832]Search in Google Scholar
[26. DiPaola J, Federici AB, Mannucci PM, Canciani MT, Kritzik M, Kunicki TJ, Nugent D. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999; 93: 3578-82.10.1182/blood.V93.11.3578]Search in Google Scholar
[27. Marshall PW, Williams AJ, Dixon RM, Growcott JW, Warburton S, Armstrong J, Moores J. A compa - rison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997; 44: 151-5.10.1046/j.1365-2125.1997.00639.x20428139278200]Search in Google Scholar